AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Heron Therapeutics Q1 revenue at $38.9mln, raises FY25 adj. EBITDA guidance.
ByAinvest
Tuesday, May 6, 2025 7:48 am ET1min read
• Heron Therapeutics reported Q1 2025 net revenue of $38.9mln, a record. • Adjusted EBITDA reached $6.2mln for Q1 2025. • The company reached a settlement with Mylan Pharmaceuticals for CINVANTI and APONVIE patent litigations. • Adjusted EBITDA guidance for full year 2025 raised to $4-$12mln. • Heron Therapeutics is well-positioned for future growth with its lead product ZYNRELEF.
Heron Therapeutics (NASDAQ: HRTX) reported its Q1 2025 earnings today, showcasing a significant milestone in the company's financial performance. The company reported a record net revenue of $38.9 million, marking a notable achievement for the biopharmaceutical firm.The company's adjusted EBITDA reached $6.2 million for the quarter, indicating a robust operational performance. This figure underscores Heron Therapeutics' ability to manage costs effectively while generating revenue. Additionally, the company has resolved patent litigation with Mylan Pharmaceuticals, further enhancing its financial stability and operational focus.
In a move that signals confidence in its future prospects, Heron Therapeutics has raised its full-year 2025 adjusted EBITDA guidance to a range of $4 million to $12 million. This upward revision reflects the company's expectation of continued growth and operational efficiency.
Heron Therapeutics is well-positioned for future growth, particularly with its lead product ZYNRELEF. The company's historical track record of beating earnings estimates, with 50% of EPS estimates and 63% of revenue estimates exceeded over the last two years, underscores its ability to deliver strong financial results [1].
As Heron Therapeutics continues to navigate the dynamic biopharmaceutical landscape, its Q1 2025 results highlight the company's resilience and strategic positioning. Investors and financial professionals should closely monitor the company's progress, particularly as it continues to develop and commercialize its innovative therapies.
References:
[1] https://seekingalpha.com/news/4441066-heron-therapeutics-q1-2025-earnings-preview
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet